

Special Issue

Immune Response and Vaccines Against Tick-Borne Pathogens

Message from the Guest Editor

Over the last few decades, numerous tick-borne diseases have been identified, many of which are caused by emerging zoonotic pathogens that pose a significant threat to the health of humans, companion animals, and agricultural livestock. It is thus crucial to conduct advanced research focused on translational goals in this area. Developing novel vaccines is a key preventive strategy for reducing the risk of tick-borne diseases. Given the limited therapeutic options for tick-transmitted bacterial, viral, and parasitic infections, it is essential to prioritize vaccine development. Innovative vaccine strategies could include new targeted approaches, such as genetically modified live vaccines, as well as techniques to stimulate a robust immune memory response against tick-transmitted pathogens.

For this Special Issue, we invite research articles, review articles, and short communications that focus on **optimal immunization strategies** and **the ongoing development of vaccines against various tick-borne diseases of both veterinary and human significance**.

Guest Editor

Prof. Dr. Roman Ganta

Department of Pathobiology and Integrative Biomedical Sciences,
College of Veterinary Medicine, University of Missouri, Columbia, MO
65211, USA

Deadline for manuscript submissions

30 November 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/262918

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers
Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.5 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2026).